Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
84.65
-2.67 (-3.06%)
At close: Jul 31, 2026, 4:00 PM EDT
84.00
-0.65 (-0.77%)
After-hours: Jul 31, 2026, 4:47 PM EDT
Arrowhead Pharmaceuticals Employees
Arrowhead Pharmaceuticals had 711 employees as of September 30, 2025. The number of employees increased by 102 or 16.75% compared to the previous year.
Employees
711
Change (1Y)
102
Growth (1Y)
16.75%
Revenue / Employee
$874,837
Profits / Employee
-$423,221
Market Cap
11.92B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 711 | 102 | 16.75% |
| Sep 30, 2024 | 609 | 84 | 16.00% |
| Sep 30, 2023 | 525 | 128 | 32.24% |
| Sep 30, 2022 | 397 | 68 | 20.67% |
| Sep 30, 2021 | 329 | 97 | 41.81% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BioMarin Pharmaceutical | 3,221 |
| Bio-Techne | 3,100 |
| Axsome Therapeutics | 1,220 |
| Exelixis | 1,077 |
| Madrigal Pharmaceuticals | 915 |
| Corcept Therapeutics | 730 |
| Cytokinetics | 673 |
| Krystal Biotech | 295 |
ARWR News
- 1 day ago - Arrowhead price target raised to $123 from $101 at B. Riley - TheFly
- 4 days ago - Arrowhead completes enrollment in Phase 3 YOSEMITE trial - TheFly
- 4 days ago - Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia - Business Wire
- 4 days ago - Arrowhead price target raised to $115 from $100 at H.C. Wainwright - TheFly
- 8 days ago - Arrowhead price target raised to $120 from $100 at Morgan Stanley - TheFly
- 8 days ago - Arrowhead price target raised to $126 from $110 at Piper Sandler - TheFly
- 9 days ago - Arrowhead price target raised to $115 from $90 at Chardan - TheFly
- 9 days ago - Arrowhead Pharmaceuticals (ARWR) Stock Soars on Strong Phase 3 Trial Results - TipRanks